The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

Scalp psoriasis can run the gamut from mild — with thin scales or plaques that are hardly discernible — to severe, with plaques and scales that cover the scalp, forehead, back of the neck ...

LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept DELTA NEXT trial. The trial aims to evaluate the efficacy and safety of ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze Prasowym”, których autorami są zarejestrowani użytkownicy tacy jak agencje PR, ...

“Although psoriasis plaques are different from plaques in the ... when you have a psoriasis flare or whether the attack will be mild or severe, there are steps you can take to both manage ...

Although itchiness is a common symptom of psoriasis, it can vary in appearance from one person to another. Psoriasis plaques are typically characterized by their pink-to-red color. These features ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

“In clinical trials, ZORYVE foam not only effectively cleared psoriasis plaques on the body and scalp ... adolescents ages 12 years and older with mild to severe plaque psoriasis of scalp ...

Treatment with guselkumab in patients with plaque psoriasis was associated with improvements in 3 biomarkers, yet greater improvements were seen with adalimumab and similar improvements were seen with ...